Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    FANCONI ANEMIA, COMPLEMENTATION GROUP B
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
Condition: Hepatitis C
Interventions: Drug: TMC435;   Drug: Ribavirin (R);   Drug: PegIFNα-2a (P);   Drug: Placebo

Indicates status has not been verified in more than two years